Insider trade

CFO sold ~$414K of UTHR shares in the open market

Traded Dec 15, 2025 · Filed Dec 17, 2025

Why it stands out

The CFO of United Therapeutics sold $414K of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

CFO$100K–$500KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$413,958

Shares × reported transaction price

Timing vs results

47 days after results of Oct 29, 2025, 72 days before results of Feb 25, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	+0.7%	+2.8%	−2.1%
30 days	−9.0%	+3.0%	−12.0%
90 days	+5.7%	−0.1%	+5.8%
180 days	+7.6%	+12.4%	−4.9%

Past results only. Not a forecast.

This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025.
This transaction was executed in multiple trades at prices ranging from $492.28 to $493.24. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Filed 9mo ago

Traded Jan 15 · filed 1 day later

Derivative exercise or conversion — not an open-market buy.

Scheduled in advanceFiled 9mo ago

Scheduled in advanceFiled 9mo ago